Clinical Sciences
The Clinical Sciences Division of our organization represents the delivery of state of the art diagnosis and treatment to patients. From laboratory bench to bedside, the Clinical Research Division works to develop and analyze new prevention, diagnostic and treatment options for cancers. This Division is anticipated to be composed of at least 10 departments; clinical oncology services, hematological oncology, urological oncology, women's oncology, radiation oncology, radiology, pathology, transplantation, health outcomes and surgical oncology. This division also contains a Phase I clinical trials unit and it brings together physician investigators into multidisciplinary teams which will focus on certain types of cancer, and thereby identify and apply new research areas which can be pursued in order to prevent or cure or better palliate that type of cancer. Utilizing a comprehensive approach to care, many of our physicians will be involved in laboratory research and the development of clinical trials. Along with a dedicated support team, many members of this division will be involved in direct patient and family care. An example of such an approach will be in prostate cancer where the decision to undergo treatment with either radiation or surgery is often a difficult one for the patients and family to make. Based upon patient and family preferences, currently recognized "best therapy", clinical factors, pathologic factors, socioeconomic factors, and potential biological factors (ie hedgehog signaling pathway expression) we expect that the team of specialists at the NVCI will make a "best therapy" recommendation. With prospective collection of the information used to make the decision, development of new information and long-term follow-up of prostate cancer survivors, the clinical scientists at the NVCI will analyze the outcomes (ie rate of cancer cure) and refine their "best therapy" recommendations.
Phase I (Investigational Therapeutics)
Hematologic Oncology
Urologic Oncology
Radiation Oncology